

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
July 18, 2013**

**ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

Sorrento Therapeutics, Inc.

File No. 0-52228 - CF#29771

Sorrento Therapeutics, Inc. submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 10-Q filed on May 15, 2013 and, as amended, to a Form 10-Q/A filed on July 12, 2013.

Based on representations by Sorrento Therapeutics, Inc., as revised, that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

Exhibit 2.1	through May 13, 2023
Exhibit 10.3	through May 13, 2023
Exhibit 10.4	through May 13, 2023

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Elizabeth M. Murphy
Secretary